Back to top
more

Option Care Health (OPCH)

(Delayed Data from NSDQ)

$27.52 USD

27.52
1,006,803

+0.54 (2.00%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $27.54 +0.02 (0.07%) 7:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Option Care (OPCH) Beats Q2 Earnings and Revenue Estimates

Option Care (OPCH) delivered earnings and revenue surprises of 125.00% and 9.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Option Care (OPCH) Reports Next Week: Wall Street Expects Earnings Growth

Option Care (OPCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Option Care (OPCH) Reports Q1 Loss, Tops Revenue Estimates

Option Care (OPCH) delivered earnings and revenue surprises of -200.00% and 0.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Is Option Care Health (OPCH) Outperforming Other Medical Stocks This Year?

Is (OPCH) Outperforming Other Medical Stocks This Year?

Option Care (OPCH) Q4 Earnings and Revenues Beat Estimates

Option Care (OPCH) delivered earnings and revenue surprises of 42.86% and 0.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Option Care (OPCH) Dips More Than Broader Markets: What You Should Know

Option Care (OPCH) closed at $19.54 in the latest trading session, marking a -1.19% move from the prior day.

What's in Store for Fulgent Genetics (FLGT) in Q4 Earnings?

We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

DENTSPLY SIRONA's (XRAY) fourth-quarter results are likely to reflect weak segmental performance.

Option Care (OPCH) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Option Care (OPCH) closed at $18.97, marking a +0.58% move from the previous day.

Is Option Care Health (OPCH) Outperforming Other Medical Stocks This Year?

Is (OPCH) Outperforming Other Medical Stocks This Year?

Owens & Minor (OMI) to Report Q4 Earnings: What's in Store?

We expect the strength in demand for Owens & Minor's (OMI) PPEs to have continued through the fourth quarter.

Option Care (OPCH) Gains As Market Dips: What You Should Know

Option Care (OPCH) closed the most recent trading day at $19.86, moving +0.2% from the previous trading session.

Lower Bulk Purchases May Weigh on Medtronic (MDT) Q3 Earnings

Medtronic's (MDT) diabetes care, robotics surgery and neuromodulation lines are expected to have performed well in Q3.

Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?

Ecolab's (ECL) fourth-quarter results are likely to reflect gains from the Global Healthcare and Life Sciences segment.

OPKO Health (OPK) to Report Q4 Earnings: What's in Store?

OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?

Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).

Henry Schein (HSIC) to Report Q4 Earnings: What's in Store?

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q4.

Exact Sciences (EXAS) to Report Q4 Earnings: What's in the Cards?

Strength in Precision Oncology business is likely to have continued to aid Exact Sciences' (EXAS) performance in the fourth quarter of 2020 amid the coronavirus-led economic doldrums.

What's in Store for Pacific Biosciences' (PACB) Q4 Earnings?

Pacific Biosciences' (PACB) fourth-quarter results are likely to reflect strength in its Sequel system.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings

LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.

Aurora Cannabis (ACB) to Post Q2 Earnings: What's in Store?

Aurora Cannabis' (ACB) sustained consumer cannabis sales are likely to have benefited its performance in the fiscal second quarter.

Illumina (ILMN) to Report Q4 Earnings: What's in the Offing?

Illumina (ILMN) is likely to have gained during the fourth quarter from the robust performance of sequencing consumable segment.

Cerner (CERN) to Report Q4 Earnings: What's in the Offing?

Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.